Preclinical osteoarthritis

Rheumatology: Sixth Edition

Volumn 2-2, Issue , 2015, Pages 1498-1502

  Kraus, Virginia Byers ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944062733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-09138-1.00179-0     Document Type: Chapter

References (50)

1. Cibere J, Zhang H, Garnero P, et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 2009, 60:1372-1380.
2. Roemer FW, Guermazi A, Felson DT, et al. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann Rheum Dis 2011, 70:1804-1809.
3. Guermazi A, Niu J, Hayashi D, et al. Prevalence of abnormalities in knees detected by MRI in adults without knee osteoarthritis: population based observational study (Framingham Osteoarthritis Study). BMJ 2012, 345:e5339.
4. Moller I, Bong D, Naredo E, et al. Ultrasound in the study and monitoring of osteoarthritis. Osteoarthritis Cartilage 2008, 16(Suppl. 3):S4-S7.
5. Keen HI, Wakefield RJ, Grainger AJ, et al. Can ultrasonography improve on radiographic assessment in osteoarthritis of the hands? A comparison between radiographic and ultrasonographic detected pathology. Ann Rheum Dis 2008, 67:1116-1120.
6. Poole R, Blake S, Buschmann M, et al. Recommendations for the use of preclinical models in the study and treatment of osteoarthritis. Osteoarthritis Cartilage 2010, 18(Suppl. 3):S10-S16.
7. Lohmander LS, Englund PM, Dahl LL, et al. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med 2007, 35:1756-1769.
8. Lohmander LS, Dahlberg L, Ryd L, et al. Increased levels of proteoglycan fragments in knee joint fluid after injury. Arthritis Rheum 1989, 32:1434-1442.
9. Lohmander LS The release of aggrecan fragments into synovial fluid after joint injury and in osteoarthritis. J Rheumatol Suppl 1995, 43:75-77.
10. Lohmander LS, Hoerrner LA, Dahlberg L, et al. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993, 20:1362-1368.
11. Lohmander LS, Hoerrner LA, Lark MW Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993, 36:181-189.
12. Lohmander LS, Neame PJ, Sandy JD The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum 1993, 36:1214-1222.
13. Lohmander LS, Roos H, Dahlberg L, et al. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus. J Orthop Res 1994, 12:21-28.
14. Larsson S, Lohmander LS, Struglics A Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis Res Ther 2009, 11:R92.
15. Struglics A, Hansson M, Lohmander LS Human aggrecanase generated synovial fluid fragment levels are elevated directly after knee injuries due to proteolysis both in the inter globular and chondroitin sulfate domains. Osteoarthritis Cartilage 2011, 19:1047-1057.
16. Chockalingam PS, Glasson SS, Lohmander LS Tenascin-C levels in synovial fluid are elevated after injury to the human and canine joint and correlate with markers of inflammation and matrix degradation. Osteoarthritis Cartilage 2013, 21:339-345.
17. Zhang L, Yang M, Marks P, et al. Serum non-coding RNAs as biomarkers for osteoarthritis progression after ACL injury. Osteoarthritis Cartilage 2012, 20:1631-1637.
18. Lohmander LS, Atley LM, Pietka TA, et al. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003, 48:3130-3139.
19. Aurich M, Squires GR, Reiner A, et al. Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints. Arthritis Rheum 2005, 52:112-119.
20. Catterall JB, Stabler TV, Flannery CR, et al. Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Arthritis Res Ther 2010, 12:R229.
21. Sokolove J, Lepus CM Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis 2013, 5:77-94.
22. Ling SM, Patel DD, Garnero P, et al. Serum protein signatures detect early radiographic osteoarthritis. Osteoarthritis Cartilage 2009, 17:43-48.
23. Golightly Y, Marshall S, Kraus V, et al. Serum cartilage oligomeric matrix protein, hyaluronan, high-sensitivity C-reactive protein, and keratan sulfate as predictors of incident radiographic knee osteoarthritis: differences by chronic knee symptoms. Osteoarthritis Cartilage 2010, 18(Suppl. 2):S62-S63.
24. Chaganti RK, Kelman A, Lui L, et al. Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis. Osteoarthritis Cartilage 2008, 16:566-571.
25. Kelman A, Lui L, Yao W, et al. Association of higher levels of serum cartilage oligomeric matrix protein and N-telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly women. Arthritis Rheum 2006, 54:236-243.
26. Dragomir AD, Kraus VB, Renner JB, et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 2002, 10:687-691.
27. van Valburg AA, Wenting MJ, Beekman B, et al. Degenerated human articular cartilage at autopsy represents preclinical osteoarthritic cartilage: comparison with clinically defined osteoarthritic cartilage. J Rheumatol 1997, 24:358-364.
28. Thorstensson CA, Andersson ML, Jonsson H, et al. Natural course of knee osteoarthritis in middle-aged subjects with knee pain: 12-year follow-up using clinical and radiographic criteria. Ann Rheum Dis 2009, 68:1890-1893.
29. Peat G, Thomas E, Duncan R, et al. Is a "false-positive" clinical diagnosis of knee osteoarthritis just the early diagnosis of pre-radiographic disease?. Arthritis Care Res (Hoboken) 2010, 62:1502-1506.
30. Manno RL, Bingham CO, Paternotte S, et al. OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials. Osteoarthritis Cartilage 2012, 20:93-101.
31. Lories RJ, Luyten FP The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol 2011, 7:43-49.
32. Devereux RB, Alderman MH Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993, 88:1444-1455.
33. Sharif M, Kirwan JR, Elson CJ, et al. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 2004, 50:2479-2488.
34. Onnerfjord P, Khabut A, Reinholt FP, Svensson O, Heinegard D Quantitative proteomic analysis of eight cartilaginous tissues reveals characteristic differences as well as similarities between subgroups. J Biol Chem 2012, 287:18913-18924.
35. Catterall JB, Hsueh MF, Stabler TV, et al. Protein modification by deamidation indicates variations in joint extracellular matrix turnover. J Biol Chem 2012, 287:4640-4651.
36. Vincent TL Targeting mechanotransduction pathways in osteoarthritis: a focus on the pericellular matrix. Curr Opin Pharmacol 2013, 13:449-454.
37. Scanzello CR, Plaas A, Crow MK Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound?. Curr Opin Rheumatol 2008, 20:565-572.
38. Riyazi N, Slagboom E, de Craen AJ, et al. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis Rheum 2005, 52:1443-1450.
39. Goekoop RJ, Kloppenburg M, Kroon HM, et al. Low innate production of interleukin-1beta and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis Cartilage 2010, 18:942-947.
40. Catterall J, Zura R, Bolognesi M, Kraus V Amino acid racemization reveals a high state of repair in knee compared with hip osteoarthritic cartilage. Osteoarthritis and Cartilage 2013, 21:S108.
41. Muehleman C, Margulis A, Bae WC, Masuda K Relationship between knee and ankle degeneration in a population of organ donors. BMC Med 2010, 8:48.
42. Luyten FP, Lories RJ, Verschueren P, et al. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol 2006, 20:829-848.
43. Kraus V Biomarkers and osteoarthritis. Genomic and personalized medicine 2013, 983-989. Academic Press, Philadelphia. 2nd ed. G.S. Ginsburg, H.F. Willard (Eds.).
44. Lotz MK, Kraus VB New developments in osteoarthritis. Posttraumatic osteoarthritis: pathogenesis and pharmacological treatment options. Arthritis Res Ther 2010, 12:211.
45. Kotlarz H, Gunnarsson CL, Fang H, et al. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009, 60:3546-3553.
46. Murphy LB, Helmick CG, Cisternas MG, et al. Estimating medical costs attributable to osteoarthritis in the US population: comment on the article by Kotlarz et al. Arthritis Rheum 2010, 62:2566-2567.
47. Machiavelli N The prince: concerning mixed principalities Constitution Society, 1505. Available at. http://www.constitution.org/mac/prince00.htm.
48. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69:1580-1588.
49. Dale J, Porter D Pharmacotherapy: concepts of pathogenesis and emerging treatments. Optimising the strategy of care in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010, 24:443-455.
50. Kraus V Waiting for action on the osteoarthritis front. Curr Drug Targets 2010, 11:1-2.